In the pursuit to cure* chronic hepatitis C virus (HCV) genotype 1 infection...Consider once-daily OLYSIO® in combination with sofosbuvir (SOF) for your individual patient needs
OLYSIO® + SOF is the only protease inhibitor + nucleotide polymerase inhibitor regimen
Patients with chronic hepatitis C have individual treatment needs.
HCV resistance tests may help identify a patient’s viral sensitivity or resistance to available treatment regimens including the NS3/4A, NS5A, and/or NS5B classes. Review MOAs of approved genotype 1 HCV regimens in the chart below.
HCV tests for G1 are offered by major laboratory companies7-9
For those patients who may be appropriate candidates for a non-NS5A inhibitor regimen, consider if OLYSIO® is an appropriate option.
MOA=mechanism of action; PI=protease inhibitor; RBV=ribavirin.
*Virologic cure (SVR12) was defined as sustained virologic response 12 weeks after actual (OPTIMIST-1) or planned (COSMOS) end of treatment (EOT).